- Stocks
- Pharma & Healthcare
- Advanced Enzyme Technologies
Advanced Enzyme Technologies share price
NSE: ADVENZYMESPharma & HealthcareSpecialty Chemicals
Advanced Enzyme Technologies at a glance
Advanced Enzyme Technologies (NSE: ADVENZYMES) closed at ₹263.30 on 21 Oct 2026. With a market capitalisation of ₹4,184 Cr, it ranks 814th by market cap among the 3,928 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Specialty Chemicals.
Its return on equity was 9.2% in FY25. Its 52-week range is ₹251.95 (30 Mar 2026) to ₹419.00 (11 May 2026); the last close is 37.2% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹203 Cr (+21.6% year on year) and net profit ₹45 Cr (+69.3%), on a consolidated basis. Promoters held 43.24% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹4,184 CrRank 814 on NSE
- Price to book
- 2.2×FY25
- EPS (TTM)
- ₹15.08to Q4 FY26
- ROE
- 9.2%FY25
- ROCE
- 12.5%FY25
- Debt to equity
- 0.02FY25
- Net profit margin
- 21.0%FY25
- Book value / share
- ₹127.00FY25
- Dividend payout
- 43.5%FY25
- 52-week high
- ₹419.0011 May 2026
- 52-week low
- ₹251.9530 Mar 2026
Returns to —
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Advanced Enzyme Technologies quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹155 Cr | ₹146 Cr | ₹169 Cr | ₹167 Cr | ₹186 Cr | ₹185 Cr | ₹172 Cr | ₹203 Cr |
| Revenue YoY | +4.9% | −7.4% | +5.1% | +5.9% | +20.3% | +26.3% | +1.7% | +21.6% |
| Net profit | ₹35 Cr | ₹33 Cr | ₹39 Cr | ₹27 Cr | ₹40 Cr | ₹45 Cr | ₹43 Cr | ₹45 Cr |
| Net profit YoY | +19.1% | −5.1% | −8.5% | −10.5% | +15.6% | +34.0% | +11.1% | +69.3% |
| Net margin | 22.6% | 22.9% | 23.0% | 16.0% | 21.8% | 24.2% | 25.1% | 22.3% |
| EPS | ₹3.05 | ₹2.94 | ₹3.36 | ₹2.37 | ₹3.57 | ₹3.87 | ₹3.80 | ₹3.84 |
Advanced Enzyme Technologies financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹444 Cr | ₹502 Cr | ₹529 Cr | ₹541 Cr | ₹624 Cr | ₹637 Cr |
| Operating profit | ₹179 Cr | ₹210 Cr | ₹171 Cr | ₹144 Cr | ₹203 Cr | ₹187 Cr |
| Net profit | ₹133 Cr | ₹151 Cr | ₹124 Cr | ₹104 Cr | ₹137 Cr | ₹134 Cr |
| EPS (₹) | ₹12.00 | ₹13.00 | ₹11.00 | ₹9.00 | ₹12.00 | ₹12.00 |
| Cash from operations | ₹141 Cr | ₹163 Cr | ₹122 Cr | ₹140 Cr | ₹141 Cr | ₹143 Cr |
| Total debt | ₹4 Cr | ₹10 Cr | ₹8 Cr | ₹8 Cr | ₹7 Cr | ₹9 Cr |
| Shareholders' equity | ₹840 Cr | ₹971 Cr | ₹1,089 Cr | ₹1,235 Cr | ₹1,324 Cr | ₹1,421 Cr |
Advanced Enzyme Technologies shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 43.08% | 43.08% | 43.07% | 43.04% | 43.26% | 43.24% |
| Foreign institutions | 11.90% | 23.46% | 25.41% | 25.86% | 25.49% | 26.71% |
| Domestic institutions | 8.19% | 8.45% | 6.41% | 5.51% | 5.41% | 4.78% |
| Non-institutions | 36.83% | 25.02% | 25.10% | 25.59% | 25.84% | 25.27% |
Advanced Enzyme Technologies vs peers
The listed Pharma & Healthcare companies nearest to Advanced Enzyme Technologies by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ENTEROEntero Healthcare Solutions | — | — | — | ₹4,741 Cr | — | — |
| GUJTHEMGujarat Themis Biosyn | — | — | — | ₹4,186 Cr | — | — |
| ADVENZYMESAdvanced Enzyme Technologies | — | — | — | ₹4,184 Cr | — | — |
| ZOTAZota Health Care | — | — | — | ₹3,966 Cr | — | — |
| IOLCPIOL Chemicals and Pharmaceuticals | — | — | — | ₹3,822 Cr | — | — |
| RPGLIFERPG Life Sciences | — | — | — | ₹3,766 Cr | — | — |
| GUFICBIOGufic Biosciences | — | — | — | ₹3,562 Cr | — | — |
Ask anything about Advanced Enzyme Technologies
Pivot answers on the live chart with evidence you can check, and tests strategies against ADVENZYMES's own history. Try: “Why has ADVENZYMES moved over the last three months?” · “Backtest a 50-day moving-average crossover on ADVENZYMES over five years” · “Compare ADVENZYMES with ENTERO on margins and valuation”
Frequently asked questions about Advanced Enzyme Technologies
What is the share price of Advanced Enzyme Technologies today?
Advanced Enzyme Technologies (NSE: ADVENZYMES) last closed at ₹263.30 on 21 Oct 2026. Its 52-week high is ₹419.00 and its 52-week low is ₹251.95.
What is the market cap of Advanced Enzyme Technologies?
Advanced Enzyme Technologies' market capitalisation is ₹4,184 Cr (₹4,184 Cr) at the — close, ranking 814th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Advanced Enzyme Technologies?
Return on equity was 9.2% in FY25 and return on capital employed was 12.5% in FY25 (consolidated figures).
Is Advanced Enzyme Technologies a debt-free company?
Advanced Enzyme Technologies is close to debt-free: its debt-to-equity ratio was 0.02 in FY25.
What were Advanced Enzyme Technologies' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Advanced Enzyme Technologies reported revenue of ₹203 Cr, +21.6% year on year, and net profit of ₹45 Cr, +69.3% year on year.
What is the shareholding pattern of Advanced Enzyme Technologies?
As of 30 Jun 2026: promoters 43.24%, foreign institutions 26.71%, domestic institutions 4.78%, non-institutions 25.27%.
Who are Advanced Enzyme Technologies' competitors?
The listed Pharma & Healthcare companies closest to Advanced Enzyme Technologies by market cap are Entero Healthcare Solutions, Gujarat Themis Biosyn, Zota Health Care, IOL Chemicals and Pharmaceuticals, RPG Life Sciences and Gufic Biosciences.
Is Advanced Enzyme Technologies a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Advanced Enzyme Technologies' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ADVENZYMES against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 21 Oct 2026. Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 3,928 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text